In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy

Toshiro Shirakawa, Song Chu Ko, Thomas A. Gardner, Jun Cheon, Tadayuki Miyamoto, Akinobu Gotoh, Leland W.K. Chung, Chinghai Kao

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Pulmonary metastases are the main cause of death of patients with several types of cancer, including osteosarcoma, renal cell carcinoma, malignant melanoma, and breast cancer. Previously, we demonstrated that intralesional injection of the recombinant adenovirus (Ad) vector containing the herpes simplex virus thymidine kinase (TK) gene driven by an osteocalcin (OC) promoter (Ad-OC-TK) effectively suppressed the growth of osteosarcoma cells in vitro and tumors in vivo in a tumor-specific manner when supplemented with the prodrug acyclovir (ACV). In this communication, we studied the potential efficacy of the treatment of osteosarcoma pulmonary metastases with a systemic delivery route of Ad-OC-TK supplemented with ACV. We established osteosarcoma lung metastases in nude mice by the intravenous injection of rat osteosarcoma cells, ROS 17/2.8. These cells colonized and formed tumor nodules within 1 week in the lungs of nude mice. Whereas systemic delivery of a recombinant Ad vector containing the Escherichia coli β-galactosidase (β-gal) gene driven by a Rous sarcoma virus universal promoter (Ad-RSV-β-gal) resulted in the nonspecific expression of β-gal activity in the lung parenchyma, Ad-OC-β-gal administration resulted in specific β-gal expression in tumor cells deposited in the lung. When nude mice bearing ROS 17/2.8 lung tumors were treated with systemic Ad-OC-TK through tail vein administration, subsequent intraperitoneal ACV treatment significantly decreased the number of tumor nodules (P < .0001) and the net lung wet weight (P = .0005) while significantly increasing (.005 < P < .01) the survival of animals, when compared with untreated and Ad-OC-TK- or ACV-treated control groups. These results suggest that Ad-OC-TK/ACV may be used as a systemic therapy for the treatment of osteosarcoma lung metastasis.

Original languageEnglish
Pages (from-to)274-280
Number of pages7
JournalCancer Gene Therapy
Volume5
Issue number5
Publication statusPublished - 1998 Dec 1

Fingerprint

Poisons
Osteocalcin
Osteosarcoma
Adenoviridae
Genetic Therapy
Thymidine Kinase
Neoplasm Metastasis
Acyclovir
Lung
Neoplasms
Nude Mice
Galactosidases
Intralesional Injections
Rous sarcoma virus
Prodrugs
Pulmonary Edema
Simplexvirus
Renal Cell Carcinoma
Intravenous Injections
Genes

Keywords

  • Adenovirus
  • Osteocalcin promoter
  • Osteosarcoma
  • Pulmonary metastasis
  • Thymidine kinase
  • Toxic gene therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Shirakawa, T., Ko, S. C., Gardner, T. A., Cheon, J., Miyamoto, T., Gotoh, A., ... Kao, C. (1998). In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Therapy, 5(5), 274-280.

In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. / Shirakawa, Toshiro; Ko, Song Chu; Gardner, Thomas A.; Cheon, Jun; Miyamoto, Tadayuki; Gotoh, Akinobu; Chung, Leland W.K.; Kao, Chinghai.

In: Cancer Gene Therapy, Vol. 5, No. 5, 01.12.1998, p. 274-280.

Research output: Contribution to journalArticle

Shirakawa, T, Ko, SC, Gardner, TA, Cheon, J, Miyamoto, T, Gotoh, A, Chung, LWK & Kao, C 1998, 'In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy', Cancer Gene Therapy, vol. 5, no. 5, pp. 274-280.
Shirakawa, Toshiro ; Ko, Song Chu ; Gardner, Thomas A. ; Cheon, Jun ; Miyamoto, Tadayuki ; Gotoh, Akinobu ; Chung, Leland W.K. ; Kao, Chinghai. / In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. In: Cancer Gene Therapy. 1998 ; Vol. 5, No. 5. pp. 274-280.
@article{f3160a63ae7643e09d625a3804f9af18,
title = "In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy",
abstract = "Pulmonary metastases are the main cause of death of patients with several types of cancer, including osteosarcoma, renal cell carcinoma, malignant melanoma, and breast cancer. Previously, we demonstrated that intralesional injection of the recombinant adenovirus (Ad) vector containing the herpes simplex virus thymidine kinase (TK) gene driven by an osteocalcin (OC) promoter (Ad-OC-TK) effectively suppressed the growth of osteosarcoma cells in vitro and tumors in vivo in a tumor-specific manner when supplemented with the prodrug acyclovir (ACV). In this communication, we studied the potential efficacy of the treatment of osteosarcoma pulmonary metastases with a systemic delivery route of Ad-OC-TK supplemented with ACV. We established osteosarcoma lung metastases in nude mice by the intravenous injection of rat osteosarcoma cells, ROS 17/2.8. These cells colonized and formed tumor nodules within 1 week in the lungs of nude mice. Whereas systemic delivery of a recombinant Ad vector containing the Escherichia coli β-galactosidase (β-gal) gene driven by a Rous sarcoma virus universal promoter (Ad-RSV-β-gal) resulted in the nonspecific expression of β-gal activity in the lung parenchyma, Ad-OC-β-gal administration resulted in specific β-gal expression in tumor cells deposited in the lung. When nude mice bearing ROS 17/2.8 lung tumors were treated with systemic Ad-OC-TK through tail vein administration, subsequent intraperitoneal ACV treatment significantly decreased the number of tumor nodules (P < .0001) and the net lung wet weight (P = .0005) while significantly increasing (.005 < P < .01) the survival of animals, when compared with untreated and Ad-OC-TK- or ACV-treated control groups. These results suggest that Ad-OC-TK/ACV may be used as a systemic therapy for the treatment of osteosarcoma lung metastasis.",
keywords = "Adenovirus, Osteocalcin promoter, Osteosarcoma, Pulmonary metastasis, Thymidine kinase, Toxic gene therapy",
author = "Toshiro Shirakawa and Ko, {Song Chu} and Gardner, {Thomas A.} and Jun Cheon and Tadayuki Miyamoto and Akinobu Gotoh and Chung, {Leland W.K.} and Chinghai Kao",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "5",
pages = "274--280",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy

AU - Shirakawa, Toshiro

AU - Ko, Song Chu

AU - Gardner, Thomas A.

AU - Cheon, Jun

AU - Miyamoto, Tadayuki

AU - Gotoh, Akinobu

AU - Chung, Leland W.K.

AU - Kao, Chinghai

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Pulmonary metastases are the main cause of death of patients with several types of cancer, including osteosarcoma, renal cell carcinoma, malignant melanoma, and breast cancer. Previously, we demonstrated that intralesional injection of the recombinant adenovirus (Ad) vector containing the herpes simplex virus thymidine kinase (TK) gene driven by an osteocalcin (OC) promoter (Ad-OC-TK) effectively suppressed the growth of osteosarcoma cells in vitro and tumors in vivo in a tumor-specific manner when supplemented with the prodrug acyclovir (ACV). In this communication, we studied the potential efficacy of the treatment of osteosarcoma pulmonary metastases with a systemic delivery route of Ad-OC-TK supplemented with ACV. We established osteosarcoma lung metastases in nude mice by the intravenous injection of rat osteosarcoma cells, ROS 17/2.8. These cells colonized and formed tumor nodules within 1 week in the lungs of nude mice. Whereas systemic delivery of a recombinant Ad vector containing the Escherichia coli β-galactosidase (β-gal) gene driven by a Rous sarcoma virus universal promoter (Ad-RSV-β-gal) resulted in the nonspecific expression of β-gal activity in the lung parenchyma, Ad-OC-β-gal administration resulted in specific β-gal expression in tumor cells deposited in the lung. When nude mice bearing ROS 17/2.8 lung tumors were treated with systemic Ad-OC-TK through tail vein administration, subsequent intraperitoneal ACV treatment significantly decreased the number of tumor nodules (P < .0001) and the net lung wet weight (P = .0005) while significantly increasing (.005 < P < .01) the survival of animals, when compared with untreated and Ad-OC-TK- or ACV-treated control groups. These results suggest that Ad-OC-TK/ACV may be used as a systemic therapy for the treatment of osteosarcoma lung metastasis.

AB - Pulmonary metastases are the main cause of death of patients with several types of cancer, including osteosarcoma, renal cell carcinoma, malignant melanoma, and breast cancer. Previously, we demonstrated that intralesional injection of the recombinant adenovirus (Ad) vector containing the herpes simplex virus thymidine kinase (TK) gene driven by an osteocalcin (OC) promoter (Ad-OC-TK) effectively suppressed the growth of osteosarcoma cells in vitro and tumors in vivo in a tumor-specific manner when supplemented with the prodrug acyclovir (ACV). In this communication, we studied the potential efficacy of the treatment of osteosarcoma pulmonary metastases with a systemic delivery route of Ad-OC-TK supplemented with ACV. We established osteosarcoma lung metastases in nude mice by the intravenous injection of rat osteosarcoma cells, ROS 17/2.8. These cells colonized and formed tumor nodules within 1 week in the lungs of nude mice. Whereas systemic delivery of a recombinant Ad vector containing the Escherichia coli β-galactosidase (β-gal) gene driven by a Rous sarcoma virus universal promoter (Ad-RSV-β-gal) resulted in the nonspecific expression of β-gal activity in the lung parenchyma, Ad-OC-β-gal administration resulted in specific β-gal expression in tumor cells deposited in the lung. When nude mice bearing ROS 17/2.8 lung tumors were treated with systemic Ad-OC-TK through tail vein administration, subsequent intraperitoneal ACV treatment significantly decreased the number of tumor nodules (P < .0001) and the net lung wet weight (P = .0005) while significantly increasing (.005 < P < .01) the survival of animals, when compared with untreated and Ad-OC-TK- or ACV-treated control groups. These results suggest that Ad-OC-TK/ACV may be used as a systemic therapy for the treatment of osteosarcoma lung metastasis.

KW - Adenovirus

KW - Osteocalcin promoter

KW - Osteosarcoma

KW - Pulmonary metastasis

KW - Thymidine kinase

KW - Toxic gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0032151946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032151946&partnerID=8YFLogxK

M3 - Article

C2 - 9824046

AN - SCOPUS:0032151946

VL - 5

SP - 274

EP - 280

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 5

ER -